BR112023005207A2 - Lipídios catiônicos à base de piperazina - Google Patents

Lipídios catiônicos à base de piperazina

Info

Publication number
BR112023005207A2
BR112023005207A2 BR112023005207A BR112023005207A BR112023005207A2 BR 112023005207 A2 BR112023005207 A2 BR 112023005207A2 BR 112023005207 A BR112023005207 A BR 112023005207A BR 112023005207 A BR112023005207 A BR 112023005207A BR 112023005207 A2 BR112023005207 A2 BR 112023005207A2
Authority
BR
Brazil
Prior art keywords
piperazine
based cation
cation lipids
useful
lipids
Prior art date
Application number
BR112023005207A
Other languages
English (en)
Inventor
Karmakar Saswata
Dasari Ramesh
Landis Ryan
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Publication of BR112023005207A2 publication Critical patent/BR112023005207A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LIPÍDIOS CATIÔNICOS À BASE DE PIPERAZINA. A presente invenção refere-se, em parte, a compostos lipídicos à base de piperazina de Fórmula (I') e suas subfórmulas, ou um sal farmaceuticamente aceitável do mesmo. Os compostos fornecidos neste documento podem ser úteis para a entrega e expressão de mRNA e proteína codificada, por exemplo, como um componente do veículo de entrega lipossomal e, consequentemente, podem ser úteis para o tratamento de várias doenças, distúrbios e condições, como aqueles associados à deficiência de um ou mais proteínas.
BR112023005207A 2020-09-23 2021-09-23 Lipídios catiônicos à base de piperazina BR112023005207A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063082101P 2020-09-23 2020-09-23
PCT/US2021/051763 WO2022066916A1 (en) 2020-09-23 2021-09-23 Piperazine-based cationic lipids

Publications (1)

Publication Number Publication Date
BR112023005207A2 true BR112023005207A2 (pt) 2023-04-25

Family

ID=78414070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005207A BR112023005207A2 (pt) 2020-09-23 2021-09-23 Lipídios catiônicos à base de piperazina

Country Status (11)

Country Link
US (1) US20230357166A1 (pt)
EP (1) EP4216933A1 (pt)
JP (1) JP2023542944A (pt)
KR (1) KR20230074526A (pt)
CN (1) CN116457027A (pt)
AU (1) AU2021349262A1 (pt)
BR (1) BR112023005207A2 (pt)
CA (1) CA3193347A1 (pt)
IL (1) IL301536A (pt)
MX (1) MX2023003344A (pt)
WO (1) WO2022066916A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099003A1 (en) * 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
WO2023178167A1 (en) * 2022-03-16 2023-09-21 Translate Bio, Inc. Asymmetric piperazine-based cationic lipids
WO2023198857A1 (en) 2022-04-13 2023-10-19 Sanofi "good" buffer-based cationic lipids
US20240150306A1 (en) * 2022-09-27 2024-05-09 Reinvigoron Theratech, Inc. Compounds with cleavable disulfide moieties
CN116082275B (zh) * 2023-03-13 2023-07-14 北京悦康科创医药科技股份有限公司 一种脾脏中高表达的阳离子脂质化合物、包含其的组合物及用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
AU2010259984B2 (en) 2009-06-10 2017-03-09 Arbutus Biopharma Corporation Improved lipid formulation
UA121863C2 (uk) * 2014-06-24 2020-08-10 Транслейт Байо, Інк. Стереохімічно збагачені композиції для доставки нуклеїнових кислот
JP2019533707A (ja) 2016-11-10 2019-11-21 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス

Also Published As

Publication number Publication date
CA3193347A1 (en) 2022-03-31
WO2022066916A1 (en) 2022-03-31
MX2023003344A (es) 2023-06-05
CN116457027A (zh) 2023-07-18
KR20230074526A (ko) 2023-05-30
JP2023542944A (ja) 2023-10-12
EP4216933A1 (en) 2023-08-02
US20230357166A1 (en) 2023-11-09
AU2021349262A1 (en) 2023-06-08
IL301536A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112023005207A2 (pt) Lipídios catiônicos à base de piperazina
Russo et al. Rapamycin and fasting sustain autophagy response activated by ischemia/reperfusion injury and promote retinal ganglion cell survival
Piras et al. Activation of autophagy in a rat model of retinal ischemia following high intraocular pressure
Alluri et al. Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition
Shao et al. Enhancement of autophagy by histone deacetylase inhibitor trichostatin a ameliorates neuronal apoptosis after subarachnoid hemorrhage in rats
Zhao et al. P2X7 receptor suppression preserves blood-brain barrier through inhibiting RhoA activation after experimental intracerebral hemorrhage in rats
Shaul et al. Role of plasmalemmal caveolae in signal transduction
CY1119122T1 (el) Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας
Hunter et al. Hsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cells
Wang et al. 7, 8-dihydroxyflavone, a small-molecule tropomyosin-related kinase B (TrkB) agonist, attenuates cerebral ischemia and reperfusion injury in rats
BR0211807A (pt) Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos
CO2018000858A2 (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl
Lan et al. Mechanosensitive TRPV4 is required for crystal-induced inflammation
BR0307819A (pt) Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais
BRPI0509863A (pt) liberação de fármaco para fundo de olho
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
BR112014016887A2 (pt) potencialização do transporte de moléculas terapêu-ticas através da barreira hematoencefálica
BR0212841A (pt) Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
BRPI0411868A (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
US10226507B2 (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
BR112022021823A2 (pt) Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria
Gupta et al. TrkB receptor agonist 7, 8 dihydroxyflavone is protective against the inner retinal deficits induced by experimental glaucoma
BR112014001017A2 (pt) uso de um ou mais nucleotídeos para aperfeiçoar a estabilidade de calor de uma composição aquosa de caseína micelar; composição nutricional líquida; processo para o tratamento com calor de uma composição aquosa de caseína micelar; e método para prover nutrição a uma pessoa com necessidade desta
Zhao et al. MCC950 inhibits NLRP3 inflammasome and alleviates axonal injures in early stages of diffuse axonal injury in rats
Park et al. Leptin suppresses glutamate-induced apoptosis through regulation of ERK1/2 signaling pathways in rat primary astrocytes